Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: A propensity score analysis

Liver International

Volumn 36, Issue 6, 2016, Pages 817-826

  Tada, Toshifumi ^a   Kumada, Takashi ^a   Toyoda, Hidenori ^a   Kiriyama, Seiki ^a   Tanikawa, Makoto ^a   Hisanaga, Yasuhiro ^a   Kanamori, Akira ^a   Kitabatake, Shusuke ^a   Yama, Tsuyoki ^a   Tanaka, Junko ^b  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Causes of death; Eradication of HCV; Hepatitis C; Non liver related mortality; Survival

Indexed keywords

INTERFERON; URSODEOXYCHOLIC ACID; ANTIVIRUS AGENT;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CAUSE OF DEATH; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MORTALITY RATE; OUTCOME ASSESSMENT; PROPENSITY SCORE; SURVIVAL; TREATMENT RESPONSE; VIRAL CLEARANCE; COMPLICATION; GENETICS; HEPACIVIRUS; INCIDENCE; JAPAN; LIVER TUMOR; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; SUSTAINED VIROLOGIC RESPONSE;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERONS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; ROC CURVE; SUSTAINED VIROLOGIC RESPONSE;

EID: 84975727075     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13071     Document Type: Article

References (25)

1. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61: S58-68.
2. Ali A, Zein NN. Hepatitis C infection: a systemic disease with extrahepatic manifestations. Cleve Clin J Med 2005; 72: 1005-19.
3. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-33.
4. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-81.
5. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174-81.
6. Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123: 483-91.
7. Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59: 1293-302.
8. Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49: 739-44.
9. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.
10. Szabo SM, Samp JC, Walker DR, et al. Liver-specific case fatality due to chronic hepatitis C virus infection: a systematic review. Ann Hepatol 2015; 14: 618-30.
11. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
12. American Association for the Study of Liver Diseases (AASLD). Published on Recommendations for Testing, Managing, and Treating Hepatitis C. Available at http://www.hcvguidelines.org. Accessed: 1 September 2015.
13. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.
14. Omata M, Kanda T, Yu ML, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012; 6: 409-35.
15. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
16. The Japan Society of Hepatology. Surveillance algorithm and diagnostic algorithm for hepatocellular carcinoma: clinical Practice Guidelines for Hepatocellular Carcinoma. Hepatol Res 2010; 1: 6-7.
17. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
18. World Health Organization. International Classification of Diseases (ICD). Available at http://www.who.int/classifications/icd/en/. Accessed: 1 September 2015.
19. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
20. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013; 48: 452-8.
21. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-40.
22. Kobayashi M, Tanaka E, Sodeyama T, et al. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 1996; 23: 695-9.
23. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000; 79: 47-56.
24. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206: 469-77.
25. Izumi N, Asahina Y, Kurosaki M, et al. Inhibition of hepatocellular carcinoma by Peg IFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. J Gastroenterol 2013; 48: 382-90.